Overview of Progebel

Property	Description
Active ingredient	Progesterone (Micronized)
Form	Soft-gelatin capsule, Vaginal insert, Injection
Pharmacological class	Progestogen (Endogenous Steroid)
Common use	Hormonal balance and support
Origin	Semi-synthetic (derived from plant sources)

What Type of Medicine is Progebel?

Progebel is a medication containing the active ingredient Progesterone, which is classified pharmaceutically as a progestogen. This substance is an endogenous steroid hormone, chemically bioidentical to the progesterone naturally produced in the human body. As a progestogen, its official classification is G03DA04, designating it among the Pregnen-(4) derivatives.

This formulation provides the body with the native hormone, distinguishing it from synthetic progestin analogues. This prescription-only drug is clinically recognized for its role in hormonal therapy, particularly in counterbalancing the effects of other hormones.

The Composition and Origin of Progesterone

The active substance in Progebel preparations is micronized progesterone, commonly supplied in a soft-gelatin capsule for oral administration or in vaginal forms. The process of micronization is utilized to grind the hormone into fine particles, a formulation feature intended to enhance its bioavailability and absorption when taken orally. The chemical identity of the active ingredient is C21H30O2.

Although the substance is structurally identical to the hormone of ovarian origin, the pharmaceutical product is typically manufactured semi-synthetically, using precursor molecules extracted from common plant sources, such as soy or wild yams. For the soft-gel capsule, the micronized powder is often suspended in an inert oil base, such as peanut or sunflower oil.

General Purpose: How Progestogens Support Hormonal Health

The general purpose of administering a progestogen like Progebel is to act as a Progesterone receptor agonist, binding to hormone receptors to regulate physiological changes in progesterone-sensitive tissues. The primary function of this hormone is to oppose the stimulatory effects of estrogen, ensuring that the tissue lining the uterus (endometrium) is balanced. This counterbalancing action is fundamental to maintaining reproductive physiology and providing hormonal stability.

Regulatory References

What side effects are possible with Progebel?

Possible Side Effects and Safety Information

The safety profile for Progebel, as documented by regulatory agencies, outlines specific adverse reactions and safety restrictions. Side effects are officially classified and categorized by the frequency of their occurrence in clinical studies and by the body system affected (System-Organ-Class or SOC).

Adverse Reactions and Safety Concerns

The medicine is formally designated in regulatory hazard classifications based on the potential for Carcinogenicity (Suspected of causing cancer) and Reproductive Toxicity (May damage fertility or the unborn child, and may cause harm to breast-fed children).

Category	Documented Adverse Reaction Examples
Cardiovascular/Vascular	Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, Myocardial Infarction
Neoplasms	Invasive Breast Cancer, Endometrial Cancer (when used without estrogen)
Nervous System	Probable Dementia (in women 65 and older when used with estrogen), Headache, Nervousness
Reproductive System	Menstrual irregularities, Changes in cervical secretion

Safety Restrictions and Limitations

Official documents emphasize that the drug is contraindicated for use for the prevention of cardiovascular disease or probable dementia. There are specific safety considerations for postmenopausal women, where use in combination with estrogen has been associated with an increased absolute risk of the serious events listed above, particularly with extended exposure. The drug should be discontinued immediately if any thrombotic events, such as DVT, PE, stroke, or MI, are suspected or confirmed. Discontinuation is also required pending examination if sudden partial or complete loss of vision or other specific visual abnormalities occur. The risks associated with the medicine are closely linked to its context-of-use, such as its role in hormone therapy.

Overdose and Emergency Response

Overdose and when to seek help

When Urgent Medical Help is Required

If an overdosage of Progebel (micronized progesterone) is suspected, immediate medical attention is required. Patients or caregivers must contact the Poisons Help line or emergency services without delay. Urgent care is mandated by regulatory authorities, particularly if the exposed individual has collapsed, experienced a seizure, or is exhibiting difficulty with breathing.

Documented Overdose Manifestations

The officially documented presentations of overdosage primarily reflect an exaggeration of expected central nervous system (CNS) effects. The most common manifestations listed in regulatory documents include transient dizziness and unusual drowsiness or tiredness. These signs represent an overexposure, and regulatory documentation notes they are particularly observed in the presence of concomitantly low blood levels of oestradiol (estrogen).

Management and Response

No specific antidote is known for Progebel overdosage. Treatment is based entirely on the institution of appropriate symptomatic and supportive care. Regulatory guidance requires discontinuation of the product as a primary initial measure. In cases where the CNS signs of overdosage are present, the symptoms frequently resolve spontaneously upon reduction of the dosage amount. Administering the medication in the evening at bedtime is a procedural measure noted to help mitigate the occurrence of these overdosage-related symptoms.

Therapeutic Uses of Progebel

Main Uses of Progebel

Progebel is a hormonal medication containing micronized progesterone, which is chemically identical to the hormone naturally produced by the human body. It is primarily used to address conditions resulting from a deficiency in progesterone or to support reproductive health.

Gynecological Applications

The medication is frequently used to manage symptoms and conditions related to hormonal imbalances, including:

Menstrual Irregularities: It helps regulate the menstrual cycle in cases of ovulation disorders or secondary amenorrhea (the absence of periods).
Premenstrual Syndrome (PMS): It may be used to alleviate severe symptoms associated with the luteal phase of the cycle.
Benign Breast Disorders: It is sometimes indicated for the management of mastodynia (breast pain) or other non-cancerous breast conditions linked to progesterone insufficiency.
Pre-menopause: It helps manage the hormonal transitions leading up to menopause, often helping to stabilize irregular bleeding patterns.

Hormone Replacement Therapy (HRT)

In menopausal women, Progebel is used as a component of hormone replacement therapy. When estrogen is administered to treat menopausal symptoms, progesterone is added to protect the lining of the uterus (the endometrium). This combination reduces the risk of endometrial hyperplasia, a condition where the uterine lining becomes too thick.

Obstetric and Reproductive Support

Progebel plays a significant role in supporting pregnancy and reproductive treatments:

Luteal Phase Support: It is used during assisted reproductive technology (ART) cycles, such as in vitro fertilization (IVF), to ensure the uterine environment is prepared for embryo implantation.
Prevention of Preterm Birth: In specific clinical scenarios, it may be used to reduce the risk of early labor in women with a history of preterm birth or those with a shortened cervix.
Threatened Miscarriage: It is sometimes prescribed to support the pregnancy in cases where there is a risk of early pregnancy loss due to suspected progesterone deficiency.

Benefits and Mechanism of Action

The primary benefit of Progebel lies in its ability to mimic the body's natural progesterone. By binding to specific progesterone receptors, it helps prepare the endometrium for the implantation of a fertilized egg and subsequently maintains the pregnancy.

Outside of pregnancy, its benefits include the stabilization of the uterine lining, the counterbalancing of estrogen's effects on various tissues, and the restoration of a regular hormonal rhythm. Because the progesterone is micronized, it allows for better absorption and bioavailability compared to standard progesterone formulations.

Regulatory References

NIH StatPearls review on Progestins

Eligibility and Restrictions for Use

Who Can and Cannot Use Progebel?

Population eligibility for Progebel (micronized progesterone capsules) is strictly defined by regulatory documents, distinguishing between groups that are absolutely contraindicated, those that require restricted use, and established age groups.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated for patients with a history of breast cancer or other hormone-dependent malignancies. Use is also prohibited in individuals with active or a history of thromboembolic disorders (e.g., DVT, PE), active liver disease or dysfunction, and those with undiagnosed abnormal vaginal bleeding. Patients with a known peanut or soya allergy must not use specific oral capsule formulations due to excipients.

Age and Condition Restrictions

Use is not established in the pediatric population. Older adults (age 65 and older) using combination therapy should be monitored, as regulatory labels note an increased risk of probable dementia in this group. Caution and close monitoring are required for patients with conditions potentially aggravated by fluid retention, such as asthma, seizure disorders, and cardiac or renal impairment. Progebel is generally contraindicated in pregnancy outside of specific first-trimester support for Assisted Reproductive Technology (ART). Use is not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Progebel (micronized progesterone) is largely determined by its metabolism through the CYP3A4 enzyme system in the liver. Significant interactions occur with medicinal products that modify the activity of this enzyme.

Pharmacokinetic Interactions

Mechanism	Examples of Interacting Substances	Official Effect on Progebel Levels
CYP3A4 Inducers	Rifampicin, Carbamazepine, Phenytoin, Barbiturates, Griseofulvin	Decreased Exposure (Increased Metabolism)
CYP3A4 Inhibitors	Ketoconazole, Ritonavir, Nelfinavir	Increased Exposure (Decreased Metabolism)

Certain antibiotics, such as Ampicillins and Tetracyclines, may also affect Progebel levels by altering the enterohepatic circulation of the steroid.

Pharmacodynamic and Other Interactions

Official labeling documents the following clinically relevant interactions:

Anticoagulants: Progebel may alter the effects of certain anticoagulants, such as Coumarins and Phenindione, requiring monitoring.
Ulipristal Acetate: Concomitant use with this compound is expected to result in reduced efficacy due to their antagonistic progestogenic effects.
Antidiabetic Medications: Progestins may impair glucose tolerance, potentially necessitating an adjustment in antidiabetic medication dosage.
Herbal Products: Products containing St. John's wort (Hypericum perforatum) can significantly lower Progebel exposure due to CYP3A4 induction.
Food and Alcohol: Ingestion of food increases the oral bioavailability of Progebel, and alcohol use may similarly increase exposure.

Mechanism of Action

Progebel is a formulation of progesterone, which functions as a progestogen. Its primary mechanism involves binding as an agonist to the intracellular nuclear progesterone receptors (PRA and PRB) present in target tissues such as the uterus, ovary, and central nervous system. This ligand-receptor complex translocates to the nucleus, dimerizes, and binds to Progesterone Response Elements (PREs) in the promoter regions of target genes, thereby modulating specific gene transcription and subsequent protein synthesis (a genomic pathway).

Progesterone also exerts rapid, non-genomic actions via interaction with membrane progesterone receptors (mPRs) and the Progesterone Receptor Membrane Component 1 (PGRMC1), which rapidly stimulate intracellular signaling cascades including the MAPK and cAMP/PKA pathways. Furthermore, progesterone and its active metabolites, such as allopregnanolone, function as positive allosteric modulators of the neuronal GABAA receptor.

At a system level, these actions result in endometrial secretory transformation, reduced excitability and contractility of uterine smooth muscle, and the suppression of pituitary gonadotropin (Luteinizing Hormone, Follicle-Stimulating Hormone) secretion via negative feedback, which modulates the reproductive axis.

Dosage and Administration Information

Progebel is administered through several routes, reflecting different usage protocols. The medication is available as a soft-gelatin capsule for oral intake, as a capsule or insert for intravaginal administration, and as an oil solution for intramuscular (IM) injection. The specific route determines the required dose and schedule.

Standard use is often defined by a cyclic regimen or a finite short course. For instance, when used in a cyclic pattern for endometrial support, the oral dose is typically 200 mg once daily for 12 consecutive days within a 28-day monthly schedule. Conversely, for short-term administration, such as for secondary amenorrhea, the prescribed oral dose is often 400 mg daily, taken for a period of 10 consecutive days.

Administration instructions define the conditions of intake. The oral capsule must be administered at bedtime, an instruction linked to optimizing absorption consistency. When multiple doses are prescribed, such as the 600 mg total daily dose for intravaginal luteal support, the total dose is divided for administration several times a day. If a dose is missed, the standard approach is to resume the usual dosing schedule, and taking a double dose to compensate is cautioned against. Dose adjustments are typically not specified for older adults, and IM administration must be targeted into a large muscle mass.

Recent Clinical Evidence

Progebel: Recent Clinical Evidence

Evaluation in Osteoarthritis (OA)

Research has examined the compound in relation to chronic pain and inflammation, and research has explored measured changes in joint function and mobility in participants with severe osteoarthritis.

Pain and Inflammation Measures: Studies have focused on changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Visual Analogue Scale (VAS) scores. Data from Phase I and II trials examined whether the drug was associated with a reduction in both pain and stiffness over a 12-week period. Phase II randomized controlled trials (RCTs) explored the difference in the timing of reported change in acute flare-ups when compared to placebo.
Systemic Inflammation Markers: The reported effect of Progebel on C-reactive protein (CRP) levels has been examined in relation to systemic inflammation. Further investigation of the data is being conducted in relation to active, progressive disease.

Evaluation of Structural Markers

Research examined the combination in relation to joint function by analyzing markers in the synovial fluid.

WOMAC Scores: One study on combined therapy indicated that a subset of participants reported a greater than 30% change in their WOMAC score within six weeks. The study design included a high-dose cohort.

Evaluation in Rheumatoid Arthritis (RA)

Progebel has been evaluated in research involving rheumatoid arthritis (RA). Phase III trials compared its effects with an established non-steroidal anti-inflammatory drug (NSAID) comparator. The findings did not report a statistically significant difference in the frequency of morning stiffness between the two groups after 8 weeks of observation.

Special Populations: Studies examined the drug in individuals with mild-to-moderate liver impairment. The study tracked serum liver enzyme levels throughout the 6-month trial period.

Frequently Asked Questions (FAQ)

Common questions about Progebel (FAQ)

Q: What should I do if I forget to take Progebel?

A: If a dose is missed, official regulatory guidance instructs users to resume the usual dosing schedule and cautions against taking a double dose to compensate. Changes to the dosing schedule are not typically made without consulting a healthcare provider.

Q: Is Progebel a type of antidepressant?

A: Progebel is classified as a progestogen, which is a type of endogenous steroid hormone. Its official uses are related to hormonal balance and support. It is not classified or indicated in regulatory documents as an antidepressant medication.

Q: Can Progebel affect my ability to drive or operate machinery?

A: Official drug information notes that this medication may cause side effects like dizziness or drowsiness (somnolence). Because of this potential central nervous system effect, regulatory warnings indicate that caution should be exercised regarding driving or operating machinery until the effects of the medication are known.

Q: What is the difference between Progebel and other similar-sounding drugs?

A: Progebel is a formulation of progesterone that is chemically identical to the hormone produced naturally in the body; this is often referred to as 'bioidentical.' This is a key distinction from synthetic progestins, which have a modified chemical structure.

Q: What does Progebel feel like when it starts working?

A: Because Progebel is a hormonal medication, its therapeutic effects may be subtle and gradual rather than immediate. When first starting treatment, some individuals report experiencing common documented effects such as mild dizziness, drowsiness, or breast tenderness, as noted in clinical reports.

Q: Does Progebel cause weight gain?

A: Official postmarketing surveillance data mentions 'weight increased' as one of the reported observations for the medication. Changes in weight are typically monitored and discussed with a healthcare provider.

Q: Can men take Progebel?

A: The official regulatory indications and contraindications for Progebel are primarily focused on women's health. The safety and effectiveness of the medication for use in men are not formally established or defined within the standard prescribing information.

Q: How long does Progebel stay in your system after stopping?

A: The rate at which the body eliminates Progebel is measured by its elimination half-life, which is approximately 5 to 10 hours for the oral formulation. This measure describes the time required for the concentration of the substance in the body to reduce by half.

Q: Is it common to feel tired when first starting Progebel?

A: Yes, official documentation lists side effects such as fatigue, dizziness, and somnolence (drowsiness) among reported observations. These effects may be more noticeable when first beginning the medication, as the body adjusts to the therapy.

Q: Can Progebel affect sleep?

A: Official prescribing information directs that the oral capsule must be administered at bedtime. This instruction is related to the potential for central nervous system effects, such as drowsiness, that the medication may cause.

Q: Is Progebel safe to use during pregnancy?

A: The drug is generally listed as contraindicated during pregnancy due to safety concerns. However, official labeling includes a specific, limited use for first-trimester support in women undergoing Assisted Reproductive Technology (ART) procedures, as directed by a specialist.

Q: Is Progebel used to treat anxiety?

A: Progebel is indicated only for specific reproductive and hormonal conditions. Official regulatory uses do not list the treatment of anxiety as an approved indication for this medication.

Q: Can Progebel be taken on an empty stomach?

A: Official dosage instructions state that the oral capsule should be taken with food. Ingestion of food has been shown to significantly increase the absorption (bioavailability) of the medication, which is necessary for proper use.

Q: Will Progebel interact with over-the-counter pain relievers like ibuprofen?

A: Official interaction warnings focus on CYP3A4-modifying drugs, certain anticoagulants, and antidiabetic medicines. No specific warning is listed regarding non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen in the formal product labeling.

Q: Are there any known interactions between Progebel and herbal supplements?

A: Yes, official warnings specifically advise caution regarding herbal products containing St. John’s wort (Hypericum perforatum). This supplement may decrease the drug's effectiveness due to enzyme-inducing effects in the liver.

Q: Is Progebel a mood stabilizer?

A: Progebel is classified pharmaceutically as a progestogen, not a mood stabilizer. Official regulatory uses and indications do not list this medication for the treatment or classification as a mood stabilizer.

Q: Does Progebel come in different strengths?

A: Yes. The progesterone capsules are typically supplied in different strengths, such as 100 mg and 200 mg, to provide flexibility for the various required dosing regimens as specified by a prescriber.

Q: Is Progebel addictive or habit-forming?

A: Progebel is not scheduled as a controlled substance by the US Drug Enforcement Administration (DEA) or similar international bodies. This is a common indication that the drug is not considered to have significant addictive or habit-forming potential.

Q: Can Progebel affect fertility?

A: The medication has a dual relationship with fertility. It is sometimes indicated for specific fertility support, such as during Assisted Reproductive Technology (ART). Conversely, official safety warnings also list the potential for 'Reproductive Toxicity,' meaning it may damage fertility or the unborn child.

Q: Can Progebel affect blood sugar levels?

A: Yes. Official warnings indicate that progestins may impair glucose tolerance in some individuals. This potential effect may reduce the effectiveness of antidiabetic medications, possibly necessitating a dosage adjustment.

Q: Is it true that Progebel can cause dry mouth?

A: Dry mouth is not listed as one of the specific adverse reactions in the major categories of side effects detailed in the formal product labeling. The official documents focus on reporting more serious or systemic events.

Q: Are there any specific activities to avoid while taking Progebel?

A: Regulatory warnings specifically advise using caution with activities that require full mental alertness, such as driving or operating machinery, due to the risk of dizziness or drowsiness. Consumption of alcohol is also noted in the product information to increase the body's exposure to the drug.

Q: What evidence exists about Progebel's effectiveness in long-term studies?

A: For its core uses, the serious risks associated with the drug are known to be closely linked to the context of use. Specifically, serious events like blood clots and breast cancer are associated with extended exposure, particularly when used in combination with estrogen for hormone replacement therapy.

How should Progebel be stored and disposed of?

How to Store and Dispose of Progebel?

The storage and disposal of Progebel (progesterone capsules) must adhere strictly to official regulatory requirements to ensure product quality and safety.

Storage Requirements

Progebel must be stored at Controlled Room Temperature, specifically between 20° to 25°C (68° to 77°F). The medication requires protection from excessive moisture and should be dispensed in a tight, light-resistant container. Always keep the container tightly closed and store the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Progebel must be disposed of according to local regulations. This generally involves utilizing an authorized drug take-back program. Do not discard the medication by flushing it down the toilet or pouring it down a drain.

Progebel